Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Tectonic Advisors LLC

Tectonic Advisors LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 81,286 shares of the biopharmaceutical company's stock after purchasing an additional 5,580 shares during the quarter. Tectonic Advisors LLC's holdings in Gilead Sciences were worth $7,508,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. State Street Corp increased its stake in shares of Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock worth $5,044,795,000 after acquiring an additional 841,776 shares during the period. Wellington Management Group LLP grew its position in Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock worth $2,900,921,000 after purchasing an additional 11,665,593 shares during the period. FMR LLC raised its stake in shares of Gilead Sciences by 79.4% during the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after buying an additional 14,680,161 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Gilead Sciences by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock valued at $2,302,119,000 after buying an additional 574,421 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Gilead Sciences by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company's stock worth $650,009,000 after buying an additional 224,960 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $2.00 during midday trading on Friday, hitting $96.04. The company had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $100.51. The stock has a market cap of $119.69 billion, a price-to-earnings ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The business's 50-day simple moving average is $93.04 and its 200-day simple moving average is $86.76.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the company earned $2.29 EPS. The company's revenue for the quarter was up 7.0% on a year-over-year basis. On average, research analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company's stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock valued at $53,611,715 over the last ninety days. Company insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GILD. Truist Financial boosted their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a report on Friday, November 8th. Oppenheimer increased their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, December 10th. Piper Sandler lifted their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Citigroup initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a "buy" rating and a $125.00 target price on the stock. Finally, BMO Capital Markets lifted their price target on Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $98.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.